Paulo Lúcio

Paulo Lúcio

Auto-generated profile, based on publicly available information

Paulo Lúcio

Hemato-Oncology Unit, Fundação Champalimaud, 1400-038 Lisbon, Portugal

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MMMaría-Victoria Mateos
María-Victoria Mateos
MDMeletios A. Dimopoulos
Meletios A. Dimopoulos
MCMichele Cavo
Michele Cavo
KSKenshi Suzuki
Kenshi Suzuki
AJAndrzej Jakubowiak
Andrzej Jakubowiak
JSJesus San-Miguel
Jesus San-Miguel
The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with relapsed or refractory multiple myeloma. In this phase 3 trial, we randomly assigned 706 patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation to receive nine cycles of bortezomib, melphalan, and prednisone either alone (control group) or with daratumumab (daratumumab group) until disease progression. The primary end point was progression-free survival. At a median follow-up of 16.5 months in a prespecified interim analysis, the 18-month progression-free survival rate was 71.6% (95% confidence interval [CI], 65.5 to 76.8) in the daratumumab group and 50.2% (95% CI, 43.2 to 56.7) in the control group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.38 to 0.65; P<0.001). The overall response rate was 90.9% in the daratumumab group, as compared with 73.9% in the control group (P<0.001), and the rate of complete response or better (including stringent complete response) was 42.6%, versus 24.4% (P<0.001). In the daratumumab group, 22.3% of the patients were negative for minimal residual disease (at a threshold of 1 tumor cell per 105 white cells), as compared with 6.2% of those in the control group (P<0.001). The most common adverse events of grade 3 or 4 were hematologic: neutropenia (in 39.9% of the patients in the daratumumab group and in 38.7% of those in the control group), thrombocytopenia (in 34.4% and 37.6%, respectively), and anemia (in 15.9% and 19.8%, respectively). The rate of grade 3 or 4 infections was 23.1% in the daratumumab group and 14.7% in the control group; the rate of treatment discontinuation due to infections was 0.9% and 1.4%, respectively. Daratumumab-associated infusion-related reactions occurred in 27.7% of the patients. Among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression or death than the same regimen without daratumumab. The daratumumab-containing regimen was associated with more grade 3 or 4 infections. (Funded by Janssen Research and Development; ALCYONE ClinicalTrials.gov number, NCT02195479.)

3 May 2012 in Leukemia
Verified
Journal Article
Open access
JDJacques J.M. van Dongen
Jacques J.M. van Dongen
LLL Lhermitte
L Lhermitte
SBS Böttcher
S Böttcher
JAJ Almeida
J Almeida
VVV H J van der Velden
V H J van der Velden
AOA Orfao
A Orfao
Most consensus leukemia & lymphoma antibody panels consist of lists of markers based on expert opinions, but they have not been validated. Here we present the validated EuroFlow 8-color antibody panels for immunophenotyping of hematological malignancies. The single-tube screening panels and multi-tube classification panels fit into the EuroFlow diagnostic algorithm with entries defined by clinical and laboratory parameters. The panels were constructed in 2–7 sequential design–evaluation–redesign rounds, using novel Infinicyt software tools for multivariate data analysis. Two groups of markers are combined in each 8-color tube: (i) backbone markers to identify distinct cell populations in a sample, and (ii) markers for characterization of specific cell populations. In multi-tube panels, the backbone markers were optimally placed at the same fluorochrome position in every tube, to provide identical multidimensional localization of the target cell population(s). The characterization markers were positioned according to the diagnostic utility of the combined markers. Each proposed antibody combination was tested against reference databases of normal and malignant cells from healthy subjects and WHO-based disease entities, respectively. The EuroFlow studies resulted in validated and flexible 8-color antibody panels for multidimensional identification and characterization of normal and aberrant cells, optimally suited for immunophenotypic screening and classification of hematological malignancies.

1 January 2020 in The Lancet
Verified
Journal Article
Closed access
María Victoria MateosMaría Victoria Mateos
María Victoria Mateos
MCMichele Cavo
Michele Cavo
JBJoan Blade
Joan Blade
MDMeletios A Dimopoulos
Meletios A Dimopoulos
KSKenshi Suzuki
Kenshi Suzuki
JSJesus San-Miguel
Jesus San-Miguel

23 October 2014 in Cytometry Part A
Verified
Journal Article
Open access
PDF file
TKTomas Kalina
Tomas Kalina
JFJuan Flores-Montero
Juan Flores-Montero
QLQuentin Lecrevisse
Quentin Lecrevisse
CPCarlos E. Pedreira
Carlos E. Pedreira
VVVincent H. J. van der Velden
Vincent H. J. van der Velden
AOAlberto Orfao
Alberto Orfao
Flow cytometric immunophenotyping has become essential for accurate diagnosis, classification, and disease monitoring in hemato‐oncology. The EuroFlow Consortium has established a fully standardized “all‐in‐one” pipeline consisting of standardized instrument settings, reagent panels, and sample preparation protocols and software for data analysis and disease classification. For its reproducible implementation, parallel development of a quality assurance (QA) program was required. Here, we report on the results of four consecutive annual rounds of the novel external QA EuroFlow program. The novel QA scheme aimed at monitoring the whole flow cytometric analysis process (cytometer setting, sample preparation, acquisition and analysis) by reading the median fluorescence intensities (MedFI) of defined lymphocytes' subsets. Each QA participant applied the predefined reagents' panel on blood cells of local healthy donors. A uniform gating strategy was applied to define lymphocyte subsets and to read MedFI values per marker. The MedFI values were compared with reference data and deviations from reference values were quantified using performance score metrics. In four annual QA rounds, we analyzed 123 blood samples from local healthy donors on 14 different instruments in 11 laboratories from nine European countries. The immunophenotype of defined cellular subsets appeared sufficiently standardized to permit unified (software) data analysis. The coefficient of variation of MedFI for 7 of 11 markers performed repeatedly below 30%, average MedFI in each QA round ranged from 86 to 125% from overall median. Calculation of performance scores was instrumental to pinpoint standardization failures and their causes. Overall, the new EuroFlow QA system for the first time allowed to quantify the technical variation that is introduced in the measurement of fluorescence intensities in a multicentric setting over an extended period of time. EuroFlow QA is a proficiency test specific for laboratories that use standardized EuroFlow protocols. It may be used to complement, but not replace, established proficiency tests. © 2014 International Society for Advancement of Cytometry

27 February 2003 in Blood
Verified
Journal Article
Closed access
PDF file
MVMaría-Belén Vidriales
María-Belén Vidriales
JPJosé J. Pérez
José J. Pérez
Norma C. GutiérrezNorma C. Gutiérrez
Norma C. Gutiérrez
JCJuana Ciudad
Juana Ciudad
PLPaulo Lucio
Paulo Lucio
JSJesús F. San-Miguel
Jesús F. San-Miguel
Investigation of minimal residual disease (MRD) in acute leukemias by immunophenotyping and/or molecular techniques is proving to be increasingly valuable for disease monitoring. In acute lymphoblastic leukemia (ALL), most MRD studies have focused on children, whereas in contrast, information on the value of MRD on adult ALL is scanty, and almost exclusively restricted to polymerase chain reaction (PCR) studies. Early response to therapy is one of the most important prognostic factors in acute leukemia, which prompted us to investigate whether or not early immunophenotypic assessment of MRD could also be a valuable tool for predicting relapse in adult patients with ALL. For that purpose we have analyzed the level of MRD during the initial phase of treatment (induction phase) by multiparameter flow cytometry in a series of 102 adolescent (older than 14 years) and adult patients with ALL. Immunophenotypic evaluation of the bone marrow (BM) at day +35 showed that patients with low MRD levels (< 0.05% leukemia-associated phenotype [LAP+] cells) had a significantly longer relapse-free survival (RFS) than patients with high MRD levels, and this prognostic influence was retained when only those patients in morphologic complete remission (mCR) at day +35 were considered (median RFS: 42 months vs 16 months; P = .001). Moreover, immunophenotyping helped to identify a small subset of patients (n = 12) with negative or low MRD levels (< 0.03% LAP+ cells) by day +14, with an excellent prognosis (projected RFS of 90% at 5 years). The contrary is true of patients who achieved late mCR (after day +35), since immunophenotypic investigation of MRD showed that, in spite of the mCR, none of the cases with more than 0.1% LAP+ cells would be relapse-free after 2 years. Multivariate analysis showed that the immunologic evaluation of MRD at day +35 was the most relevant independent prognostic parameter for adult patients with ALL, and together with age, white blood cell (WBC) count at diagnosis, and presence of the Philadelphia (Ph) chromosome, represented the most informative combination of variables for predicting relapse-free survival.

26 July 2001 in Leukemia
Verified
Journal Article
Closed access
PLP Lucio
P Lucio
GGG Gaipa
G Gaipa
ELEg van Lochem
Eg van Lochem
EWEr van Wering
Er van Wering
APA Porwit-MacDonald
A Porwit-MacDonald
FEfrom the BIOMED-1 Concerted Action ‘Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation’
from the BIOMED-1 Concerted Action ‘Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Evaluation’